SCHEMBL17149472

SCHEMBL17149472

NN=Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 1/20 0.57
▸ NOS1 P29475 4/20 0.55
▸ ALDH1A1 P00352 5/20 0.52
▸ CA12 O43570 2/20 0.52
▸ CA1 P00915 2/20 0.52
▸ CA2 P00918 2/20 0.52
▸ CA9 Q16790 2/20 0.52
▸ CA3 P07451 1/20 0.52
▸ CA4 P22748 1/20 0.52
▸ CA6 P23280 1/20 0.52
▸ CA5A P35218 1/20 0.52
▸ CA7 P43166 1/20 0.52
▸ CA13 Q8N1Q1 1/20 0.52
▸ CA14 Q9ULX7 1/20 0.52
▸ CA5B Q9Y2D0 1/20 0.52
▸ MEN1 O00255 5/20 0.51
▸ MAPT P10636 5/20 0.51
▸ KMT2A Q03164 5/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ MAPK1 P28482 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3282776 0.86 MEN1 (0.61) PLAUNOS1ALDH1A1MEN1MAPT
SCHEMBL3282773 0.86 MEN1 (0.61) PLAUNOS1ALDH1A1MEN1MAPT
SCHEMBL15922 0.81 ALDH1A1 (0.75) PLAUNOS1ALDH1A1CA12CA2
SCHEMBL15923 0.81 ALDH1A1 (0.75) PLAUNOS1ALDH1A1CA12CA2
Hydrochloric Acid SCHEMBL30872195 0.79 ALDH1A1 (0.72) PLAUNOS1ALDH1A1CA12CA2
SCHEMBL27462114 0.79 ALDH1A1 (0.64) PLAUNOS1ALDH1A1CA12CA1
SCHEMBL10092679 0.78 MEN1 (0.53) PLAUNOS1ALDH1A1MEN1MAPT
SCHEMBL270426 0.78 MEN1 (0.66) PLAUNOS1ALDH1A1MEN1MAPT
SCHEMBL270425 0.78 MEN1 (0.66) PLAUNOS1ALDH1A1MEN1MAPT
SCHEMBL29588234 0.78 MEN1 (0.66) PLAUNOS1ALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027213-A1 EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUE REGENCOR INC (US) 2026-01-29 — — US disclosed
US-20250205306-A1 USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE REGENCOR, INC. 2025-06-26 — — US disclosed
EP-4499125-A1 USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE Regencor, Inc. (US) 2025-02-05 — — EP disclosed
CN-119212718-A Use of follistatin-like protein 1 (FSTL 1) in heart metabolic heart failure 雷根科公司 2024-12-27 — — CN disclosed
WO-2023183933-A1 USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE REGENCOR, INC. (US) 2023-09-28 — — WO disclosed
EP-4088733-A1 EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUE Regencor, Inc. (US) 2022-11-16 — — EP disclosed
EP-3280429-B1 FSTL1 FOR USE IN REPAIRING CARDIAC TISSUE REGENCOR INC (US) 2022-06-01 — — EP disclosed
WO-2015154023-A1 SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN X-RX DISCOVERY, INC. (US) 2015-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027213-A1 EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUE TNNI3, TNNT2, FN1 PLAU 734/4885NOS1 309/4885ALDH1A1 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback